{
    "clinical_study": {
        "@rank": "93925", 
        "arm_group": [
            {
                "arm_group_label": "Single Dose", 
                "arm_group_type": "Experimental", 
                "description": "Subjects enrolled in the Single Ascending Dose (SAD) part of the study will receive a single dose of study drug or placebo. (Groups 1, 2, 3, 4, 5 and 6)."
            }, 
            {
                "arm_group_label": "Multiple Dose", 
                "arm_group_type": "Experimental", 
                "description": "Subjects enrolled in the Multiple Ascending Dose (MAD) part of the study will receive multiple doses of study drug or placebo. (Groups 7, 8, 9, 10 and 11)"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the safety, tolerability and pharmacokinetics of ABT-199 in female subjects with\n      Systemic Lupus Erythematosus."
        }, 
        "brief_title": "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Lupus Erythematosus", 
        "condition_browse": {
            "mesh_term": "Lupus Erythematosus, Systemic"
        }, 
        "detailed_description": {
            "textblock": "This is a phase 1, randomized, double-blind, placebo-controlled, single-and multiple\n      ascending dose study. Up to eighty-eight subjects with Systemic Lupus Erythematosus will be\n      selected to participate. Subjects will be randomized to receive either ABT-199 or placebo.\n      Subjects will be administered ABT-199/placebo as a single dose or up to 14 days as multiple\n      doses."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of systemic lupus erythematosus for at least 6 months.\n\n          -  Documentation of at least one of the following: ANA titer >= 1:160 or positive\n             anti-dsDNA antibodies.\n\n          -  Stable systemic lupus erythematosus medication regimen.\n\n          -  Other than systemic lupus erythematosus, subject should be in general good health.\n\n        Exclusion Criteria:\n\n          -  Male.\n\n          -  Drug-induced or highly active systemic lupus erythematosus.\n\n          -  Significant autoimmune disease other than lupus.\n\n          -  Significant, uncontrolled or unstable disease in any organ."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "88", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01686555", 
            "org_study_id": "M13-093", 
            "secondary_id": "2013-000328-33"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Single Dose", 
                    "Multiple Dose"
                ], 
                "description": "Tablet", 
                "intervention_name": "ABT-199", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Single Dose", 
                    "Multiple Dose"
                ], 
                "description": "Tablet", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Clearwater", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33765"
                    }, 
                    "name": "Site Reference ID/Investigator# 89694"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 89694", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33144"
                    }, 
                    "name": "Site Reference ID/Investigator# 118637"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118637", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Site Reference ID/Investigator# 89693"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 89693", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66212"
                    }, 
                    "name": "Site Reference ID/Investigator# 78256"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 78256", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manhasset", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11030"
                    }, 
                    "name": "Site Reference ID/Investigator# 89773"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 89773", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duncansville", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16635"
                    }, 
                    "name": "Site Reference ID/Investigator# 78254"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 78254", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75231"
                    }, 
                    "name": "Site Reference ID/Investigator# 78253"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 78253", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10117"
                    }, 
                    "name": "Site Reference ID/Investigator# 107896"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 107896", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)", 
        "overall_contact": {
            "email": "imran.ghiasuddin@abbvie.com", 
            "last_name": "Imran  Ghiasuddin", 
            "phone": "847-935-5704"
        }, 
        "overall_contact_backup": {
            "email": "christa.lee@abbvie.com", 
            "last_name": "Christa  Lee, BS", 
            "phone": "847-938-5855"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Peng  Lu, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Collect all adverse events at each visit", 
                "measure": "Number of participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "From first dose of ABT-199 until 28 days after single dose of ABT-199 and until 21 days after the last multiple dose of ABT-199"
            }, 
            {
                "description": "Blood pressure, heart rate and body temperature", 
                "measure": "Physical Exam including vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "Prior to the first dose of ABT-199 until 28 days after single dose of ABT-199 and until 21 days after the last multiple dose of ABT-199"
            }, 
            {
                "description": "Hematology, Chemistry, and Urinalysis", 
                "measure": "Clinical Lab Testing", 
                "safety_issue": "Yes", 
                "time_frame": "Prior to the first dose of ABT-199 until 28 days after single dose of ABT-199 and until 21 days after the last multiple dose of ABT-199"
            }, 
            {
                "description": "ECGs done in triplicate", 
                "measure": "Electrocardiogram (ECG) Measurements", 
                "safety_issue": "Yes", 
                "time_frame": "For 24 hours after a single dose of ABT-199 and up to 24 hours after the seventh dose of multiple doses of ABT-199"
            }, 
            {
                "description": "Cmax", 
                "measure": "Maximum observed serum concentration (Cmax) of ABT-199", 
                "safety_issue": "No", 
                "time_frame": "For 72 hours after a single dose of ABT-199 and for 24 hours after the seventh dose of multiple doses of ABT-199"
            }, 
            {
                "description": "Time to Cmax", 
                "measure": "Time to Cmax (Tmax) of ABT-199", 
                "safety_issue": "No", 
                "time_frame": "For 72 hours after a single dose of ABT-199 and for 24 hours after the seventh dose of multiple doses of ABT-199"
            }, 
            {
                "description": "the area under the exposure-time curve of ABT-199 extrapolated to infinite time for single doses and up to 24 hrs for multiple doses of ABT-199", 
                "measure": "The area under the time curve (AUC) of ABT-199", 
                "safety_issue": "No", 
                "time_frame": "For 72 hours after a single dose of ABT-199 and for 24 hours after the seventh dose of multiple doses of ABT-199"
            }, 
            {
                "description": "The terminal phase elimination rate constant and the terminal elimination half-life (t1/2) of ABT-199", 
                "measure": "The terminal phase elimination rate constant and the terminal elimination half-life (t1/2) of ABT-199", 
                "safety_issue": "No", 
                "time_frame": "For 72 hours after a single dose of ABT-199"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01686555"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "explore pharmacokinetic/pharmacodynamic relationship", 
            "measure": "Measurement of lymphocyte depletion and recovery", 
            "safety_issue": "Yes", 
            "time_frame": "Prior to the first dose of ABT-199 until 28 days after single dose of ABT-199 and until 21 days after the last multiple dose of ABT-199"
        }, 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie (prior sponsor, Abbott)", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}